|
Name |
Sedoheptulose
|
| Molecular Formula | C7H14O7 | |
| IUPAC Name* |
(3S,4R,5R,6R)-1,3,4,5,6,7-hexahydroxyheptan-2-one
|
|
| SMILES |
C([C@H]([C@H]([C@H]([C@@H](C(=O)CO)O)O)O)O)O
|
|
| InChI |
InChI=1S/C7H14O7/c8-1-3(10)5(12)7(14)6(13)4(11)2-9/h3,5-10,12-14H,1-2H2/t3-,5-,6-,7-/m1/s1
|
|
| InChIKey |
HSNZZMHEPUFJNZ-SHUUEZRQSA-N
|
|
| Synonyms |
Sedoheptulose; D-sedoheptulose; D-Altro-2-heptulose; 3019-74-7; (3S,4R,5R,6R)-1,3,4,5,6,7-hexahydroxyheptan-2-one; D-altro-hept-2-ulose; 40A0W1XJ6X; D-Mannoheptulose; Galacto-heptulose; L-Galactoheptulose; D-altroheptulose; EINECS 221-166-2; UNII-40A0W1XJ6X; SCHEMBL119427; CHEBI:16802; D-Sedoheptulose, >=95% (TLC); ZINC8579422; WURCS=2.0/1,1,0/[hO1222h]/1/; Q1091415
|
|
| CAS | 3019-74-7 | |
| PubChem CID | 5459879 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 210.18 | ALogp: | -3.9 |
| HBD: | 6 | HBA: | 7 |
| Rotatable Bonds: | 6 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 138.0 | Aromatic Rings: | 0 |
| Heavy Atoms: | 14 | QED Weighted: | 0.258 |
| Caco-2 Permeability: | -5.385 | MDCK Permeability: | 0.00136296 |
| Pgp-inhibitor: | 0.011 | Pgp-substrate: | 0.298 |
| Human Intestinal Absorption (HIA): | 0.263 | 20% Bioavailability (F20%): | 0.853 |
| 30% Bioavailability (F30%): | 0.952 |
| Blood-Brain-Barrier Penetration (BBB): | 0.567 | Plasma Protein Binding (PPB): | 13.84% |
| Volume Distribution (VD): | 0.618 | Fu: | 72.99% |
| CYP1A2-inhibitor: | 0.009 | CYP1A2-substrate: | 0.021 |
| CYP2C19-inhibitor: | 0.007 | CYP2C19-substrate: | 0.051 |
| CYP2C9-inhibitor: | 0.001 | CYP2C9-substrate: | 0.075 |
| CYP2D6-inhibitor: | 0 | CYP2D6-substrate: | 0.091 |
| CYP3A4-inhibitor: | 0.002 | CYP3A4-substrate: | 0.006 |
| Clearance (CL): | 1.317 | Half-life (T1/2): | 0.818 |
| hERG Blockers: | 0.077 | Human Hepatotoxicity (H-HT): | 0.17 |
| Drug-inuced Liver Injury (DILI): | 0.866 | AMES Toxicity: | 0.051 |
| Rat Oral Acute Toxicity: | 0.01 | Maximum Recommended Daily Dose: | 0.004 |
| Skin Sensitization: | 0.078 | Carcinogencity: | 0.002 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.035 |
| Respiratory Toxicity: | 0.021 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000405 | ![]() |
0.625 | D06HZY | ![]() |
0.806 | ||
| ENC000136 | ![]() |
0.625 | D0VM8K | ![]() |
0.643 | ||
| ENC003038 | ![]() |
0.522 | D0P7EK | ![]() |
0.625 | ||
| ENC002398 | ![]() |
0.522 | D09MXS | ![]() |
0.625 | ||
| ENC000161 | ![]() |
0.500 | D02KFP | ![]() |
0.557 | ||
| ENC001267 | ![]() |
0.500 | D0T6VD | ![]() |
0.490 | ||
| ENC001002 | ![]() |
0.471 | D0B8SY | ![]() |
0.375 | ||
| ENC005901 | ![]() |
0.397 | D03MGL | ![]() |
0.278 | ||
| ENC005982 | ![]() |
0.397 | D09KDV | ![]() |
0.250 | ||
| ENC005983 | ![]() |
0.397 | D04XDT | ![]() |
0.223 | ||